{"name":"Azenta","slug":"azenta","ticker":"AZTA","exchange":"NASDAQ","domain":"azenta.com","description":"Azenta, was founded in 1978, and is based in Chelmsford, Massachusetts, United States. The company is a provider of life sciences services including genomics, cryogenic storage, automation, and informatics.","hq":"Burlington, MA, USA","founded":0,"employees":"2900","ceo":"John Marotta","sector":"Sample Management / Genomics Services","stockPrice":16.95,"stockChange":-0.08,"stockChangePercent":-0.47,"marketCap":"$782M","metrics":{"revenue":596483968,"revenueGrowth":1,"grossMargin":44.3,"rdSpend":30390000,"netIncome":-55763000,"cash":380516992,"dividendYield":0,"peRatio":27.6,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Azenta Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Azenta reported fourth quarter and full year 2023 financial results, with revenue increasing 14% year-over-year.","drugName":"","sentiment":"positive"},{"date":"2023-11-14","type":"deal","headline":"Azenta to Acquire Brooks Life Sciences","summary":"Azenta announced the acquisition of Brooks Life Sciences, expanding its capabilities in sample management and genomics services.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-04-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-05","type":"pipeline","source":"simplywall.st","summary":"Assessing Azenta (AZTA) Valuation After Recent Share Price Rebound And Margin Expansion Hopes - simplywall.st","headline":"Assessing Azenta (AZTA) Valuation After Recent Share Price Rebound And Margin Expansion Hopes","sentiment":"neutral"},{"date":"2026-04-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgJBVV95cUxQOTFSV29xd3A2VXRpTW5WYVZkbXh0eDF4RUN6SWpmV0h6TG9WTE5GdkUzS3NrMnBSdEQtNHgzWUNpbDZzMUM1eWxJTTRlb0VRVUFyZVJfWjdIQUpraUZPRHlEVWtKSnRYYjBTRzJhbXpUTkZhTzVybW9oZ2VTSW1hOS1QV1gyNVplU1BVVUZEWDRvNVhGckhYMDBfWHJjR3hsWjV2NFFMSWQteGNBVzQ3RC1hY3MtQk1Wems0N2I4Tk81REdjMW02VGprcy16cHpPRHNPMFVubDlWUnVHQ1lCUUNDakZ6dGY2aWZTVUd3TDE3c21VMjVuVi1OVnl6enFuZEduT3B5Q1A0SkVBYUR1d1g2QU04Zw?oc=5","date":"2026-03-22","type":"earnings","source":"The Globe and Mail","summary":"Q4 Earnings Highs And Lows: Azenta (NASDAQ:AZTA) Vs The Rest Of The Drug Development Inputs & Services Stocks - The Globe and Mail","headline":"Q4 Earnings Highs And Lows: Azenta (NASDAQ:AZTA) Vs The Rest Of The Drug Development Inputs & Services Stocks","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-09","type":"pipeline","source":"simplywall.st","summary":"Assessing Azenta (AZTA) Valuation After Extended Share Price Weakness - simplywall.st","headline":"Assessing Azenta (AZTA) Valuation After Extended Share Price Weakness","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxNUk1lN05FM0RGZHJfQWtEV3A3dDR2d2ZvNnJ5a2dIME02RjRJR0FNZWd6SWo3LUJKQmp0LTlCWFBsdFNGdDMyX182Uk1aY0hsZ1ZuVDUxVWszYzZ1aFU4bV9GTUNOUDZSeDhpdVZoaGttdFRuU2VzSG9maHZYRHVncnRCaGkwLW1QaFlhdmNoT0w5dUpxN1psNVRCWWpBd0p3cDB5ZkZtZVFCX1lUWWRFdFdjTnd2RmZPSGNuX0RSOW5yeU1uLUFVV1R2a2Nvb2Z1ZUMzTVUzQjZvc3ZEYUVnVlV6UTBXWjBlOUhZ?oc=5","date":"2026-03-04","type":"pipeline","source":"PR Newswire","summary":"Azenta Completes Strategic Acquisition of UK Biocentre Limited, to Expand Biorepository Capabilities - PR Newswire","headline":"Azenta Completes Strategic Acquisition of UK Biocentre Limited, to Expand Biorepository Capabilities","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOTzRqcS1SX01HY1ZPdlBJMmQ4VHllbE1xNjlTVklOLXVoYmVKeDJnQkFvLVV2Q3ZtbldDdUVPaDJBdnhqYzZzT09XWC1NMUxhOG5iYzg0a2RKVzRhMnltZG5tWHJ5aTVlUmtKN3NGcDRaZUR1emx6WnRWd2t6WC1UXzlkdDZkNjVubGh0YlQ1OUdVTkNCRkhKUFdESjVxeGlT?oc=5","date":"2026-03-04","type":"deal","source":"Stock Titan","summary":"Azenta (AZTA) acquires UK Biocentre in GBP 20.5m European hub deal - Stock Titan","headline":"Azenta (AZTA) acquires UK Biocentre in GBP 20.5m European hub deal","sentiment":"neutral"},{"date":"2026-03-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgJBVV95cUxNbDM2Vm10MHZSNEFPd1hxdkNydnF1VmJ0NkNLSmczcWJLa29wZlhDY090TjRtWW9IbWNOdlBGRlM2bTBkYV9xSzNtdHJFZkFZQW5mZHMzOU5rV0xEMHFkZzcxUlhQdVdrV19nd1ZYNUdHWTRnTjhKVlYwNW9zMklGeHU5QXdveXlWVmlnOC1ybUhUaVRQV1h1czl6VklMUkJkZjFlNjdmbWNoOHcwVFBOMG96T29XVFNRdTFuUFBtTll4TDZCcTE3b3MxcjlSWmZkRDF1eG81Y2tyTElHSzdZZ1owdVBWY01zak5IVjJocUNPWXJ3eE01LWFKTDVFT3Y3NWFxcUZOUkNqMXB6WEZJblg5NnhfQQ?oc=5","date":"2026-02-09","type":"deal","source":"PR Newswire","summary":"Azenta Life Sciences and Frontier Space Announce Strategic Partnership to Advance Space-Based Life Sciences Research Infrastructure - PR Newswire","headline":"Azenta Life Sciences and Frontier Space Announce Strategic Partnership to Advance Space-Based Life Sciences Research Inf","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxQYWR0UHF2RFpaZWRTYXVrcG1aVUMxaDJFWjRuNFJfM1o4c256SzBCalZjRTZQR1lyajdScHRjd2MxTDFLRG9KY1JwZGl3NXJhRnlYaTY1X2d6U0ZNM2V5UTNoejZudTR5c0Y2WTVQWGRZT1h4b1BoZ0JzWXh4NHZucm9lRklNN1BtejlGYnBGV2REbnp2RVdtRnlUMGZRUkdFd2UySzZ0VGZ0TEFYVGxZTy1JVFBsZC11Z2o0YnYzV2E0Uld4QkFFZExwa3BTejhpZ3dnZ0tPUjlXS016U2tiek5wdjcwUQ?oc=5","date":"2026-02-05","type":"pipeline","source":"FinancialContent","summary":"Cold Chain, High Stakes: A Deep Dive into Azenta’s (AZTA) Life Sciences Transformation - FinancialContent","headline":"Cold Chain, High Stakes: A Deep Dive into Azenta’s (AZTA) Life Sciences Transformation","sentiment":"neutral"},{"date":"2026-02-05","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQWkpWWE1zdHI3ZmQtbEJ6c1hIQ2F2aHNYV29QZ1JsaWVlMzRtNE5UTUtfTGcyUGhCSmNnV0xURkRyUDZtZWtJaUR4cnN3MG9WRzhhVnFwNmZPb1BYU01vU0N6Wk9sakU4N3l2RFE4SnI4MExxVmVERTVOY015Ykg4clBGbXFoNHdLdzhlS2pFR1Q1ejREWnBNWTFiQk5pRHlvTlR1MkJIZWtWRkIt?oc=5","date":"2026-02-04","type":"earnings","source":"TradingView","summary":"Azenta’s (NASDAQ:AZTA) Q4 CY2025: Beats On Revenue - TradingView","headline":"Azenta’s (NASDAQ:AZTA) Q4 CY2025: Beats On Revenue","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2026-02-04","type":"earnings","source":"simplywall.st","summary":"Azenta (AZTA) Returns To Quarterly EPS Loss Challenging Recent Profitability Narrative - simplywall.st","headline":"Azenta (AZTA) Returns To Quarterly EPS Loss Challenging Recent Profitability Narrative","sentiment":"neutral"},{"date":"2026-02-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Thermo Fisher Scientific","PerkinElmer","Bio-Rad Laboratories"],"therapeuticFocus":["Oncology","Genetic Diseases"],"financials":{"source":"sec_edgar+yahoo","revenue":593821000,"revenuePeriod":"2025-09-30","revenueHistory":[{"value":593821000,"period":"2025-09-30"},{"value":159192000,"period":"2025-09-30"},{"value":434629000,"period":"2025-06-30"},{"value":143855000,"period":"2025-06-30"},{"value":290774000,"period":"2025-03-31"}],"grossProfit":270280000,"grossProfitHistory":[{"period":"2025-09-30","value":270280000},{"period":"2024-09-30","value":254622000},{"period":"2023-09-30","value":239210000},{"period":"2022-09-30","value":255584000}],"rdSpend":30390000,"rdSpendHistory":[{"period":"2025-09-30","value":30390000},{"period":"2024-09-30","value":31524000},{"period":"2023-09-30","value":32141000},{"period":"2022-09-30","value":27542000}],"sgaSpend":261563000,"operatingIncome":-21673000,"operatingIncomeHistory":[{"period":"2025-09-30","value":-21673000},{"period":"2024-09-30","value":-39860000},{"period":"2023-09-30","value":-56669000},{"period":"2022-09-30","value":-23423000}],"netIncome":-55763000,"netIncomeHistory":[{"period":"2025-09-30","value":-55763000},{"period":"2024-09-30","value":-164897000},{"period":"2023-09-30","value":-14636000},{"period":"2022-09-30","value":2132859000}],"eps":-1.3,"epsHistory":[{"period":"2025-09-30","value":-1.3},{"period":"2024-09-30","value":-3.602583},{"period":"2023-09-30","value":-0.22},{"period":"2022-09-30","value":28.48}],"cash":279783000,"cashHistory":[{"period":"2025-09-30","value":279783000},{"period":"2024-09-30","value":280030000},{"period":"2023-09-30","value":678910000},{"period":"2022-09-30","value":658274000}],"totalAssets":2059582000,"totalLiabilities":332596000,"totalDebt":51244000,"equity":1726986000,"operatingCashflow":72181000,"operatingCashflowHistory":[{"period":"2025-09-30","value":72181000},{"period":"2024-09-30","value":49743000},{"period":"2023-09-30","value":5834000},{"period":"2022-09-30","value":-466046000}],"capex":-33857000,"capexHistory":[{"period":"2025-09-30","value":-33857000},{"period":"2024-09-30","value":-37392000},{"period":"2023-09-30","value":-39436000},{"period":"2022-09-30","value":-77435000}],"freeCashflow":38324000,"dividendsPaid":0,"buybacks":0,"employees":2900,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":null,"ebit":null,"ebitda":null,"period":"2026-03-31","revenue":null,"epsBasic":-3.49,"netIncome":null,"rdExpense":null,"epsDiluted":-3.49,"grossProfit":null,"operatingIncome":null},{"sga":60611000,"ebit":-6094000,"ebitda":7554000,"period":"2025-12-31","revenue":148642000,"epsBasic":-0.34,"netIncome":-15432000,"rdExpense":9189000,"epsDiluted":-0.34,"grossProfit":63706000,"operatingIncome":-6094000},{"sga":55727000,"ebit":1780000,"ebitda":16214000,"period":"2025-09-30","revenue":158951000,"epsBasic":1.03,"netIncome":50839000,"rdExpense":10456000,"epsDiluted":1.02,"grossProfit":67963000,"operatingIncome":1780000},{"sga":61035000,"ebit":40000,"ebitda":14762000,"period":"2025-06-30","revenue":143942000,"epsBasic":-1.15,"netIncome":-52806000,"rdExpense":6685000,"epsDiluted":-1.15,"grossProfit":67760000,"operatingIncome":40000},{"sga":71588000,"ebit":-12571000,"ebitda":1382000,"period":"2025-03-31","revenue":143418000,"epsBasic":-0.88,"netIncome":-40456000,"rdExpense":6869000,"epsDiluted":-0.88,"grossProfit":65886000,"operatingIncome":-12571000},{"sga":69976000,"ebit":-8270000,"ebitda":9830000,"period":"2024-12-31","revenue":147436000,"epsBasic":null,"netIncome":-10992000,"rdExpense":7113000,"epsDiluted":null,"grossProfit":68819000,"operatingIncome":-8270000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":16.95,"previousClose":17.03,"fiftyTwoWeekHigh":41.73,"fiftyTwoWeekLow":16.79,"fiftyTwoWeekRange":"16.79 - 41.73","fiftyDayAverage":22.49,"twoHundredDayAverage":29.8,"beta":1.43,"enterpriseValue":460154464,"forwardPE":27.6,"priceToBook":0.5,"priceToSales":1.31,"enterpriseToRevenue":0.77,"enterpriseToEbitda":12.53,"pegRatio":0,"ebitda":36716000,"ebitdaMargin":6.2,"freeCashflow":101328000,"operatingCashflow":62340000,"totalDebt":55711000,"debtToEquity":3.6,"currentRatio":2.83,"returnOnAssets":-0.6,"returnOnEquity":-6.8,"analystRating":"2.2 - Buy","recommendationKey":"buy","numberOfAnalysts":5,"targetMeanPrice":26.2,"targetHighPrice":33,"targetLowPrice":20,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0.83,"exDividendDate":1638403200,"insiderHeldPercent":0.9,"institutionHeldPercent":119.7,"sharesOutstanding":46092804,"floatShares":40683813,"sharesShort":5955507,"shortRatio":6.93,"shortPercentOfFloat":12.9,"epsTrailing":-2.41,"epsForward":0.61,"revenuePerShare":12.99,"bookValue":33.73,"officers":[{"age":44,"name":"Mr. John P.  Marotta","title":"President, CEO & Director"},{"age":48,"name":"Mr. Lawrence Y. Lin","title":"Executive VP & CFO"},{"age":53,"name":"Mr. Ephraim  Starr","title":"Senior VP, General Counsel & Corporate Secretary"},{"age":51,"name":"Ms. Olga  Pirogova","title":"Senior VP & Chief HR Officer"},{"age":48,"name":"Dr. Ginger  Zhou Ph.D.","title":"Advisor"},{"age":null,"name":"Mr. Michael  Paulo","title":"VP, Chief Information & Digital Officer"},{"age":null,"name":"Ms. Yvonne  Perron","title":"Vice President of Financial Planning & Analysis and Investor Relations"},{"age":null,"name":"Dr. Andrea  O'Hara Ph.D.","title":"Strategic Technical Specialist of Azenta Life Sciences"}],"industry":"Medical Instruments & Supplies","irWebsite":"http://www.brooks.com/company/investors","website":"https://www.azenta.com","phone":"888 229 3682"}}